Affiliation:
1. CARDIAC SURGERY, INTENSIVE CARE UNIT, CENTRAL CLINICAL HOSPITAL OF THE MEDICAL UNIVERSITY OF LODZ, LODZ, POLAND
2. DEPARTMENT OF ANAESTHESIA AND INTENSIVE THERAPY, SCHOOL OF HEALTH SCIENCES IN KATOWICE, MEDICAL UNIVERSITY OF SILESIA IN KATOWICE, KATOWICE, POLAND
Abstract
Aim: The authors evaluated the effectiveness of treatment with recombinant human coagulation factor VIIa and concentrate of all prothrombin complex factors in patients with massive postoperative bleeding that could not be controlled with traditional therapy.
Materials and Methods: In the period from 2020 to 2021, recombinant human coagulation factor VIIa was administered to 18 patients after cardiac surgery (group I), while the concentrate of all prothrombin complex factors was administered to 16 patients postoperatively (group II). During this period, 647 patients were operated on. The patients had normal coagulation screening tests (APTT, INR, TT, fibrinogen level, and PLT level) before surgery. Mean blood loss before and after administration of eptacog alfa and the total prothrombin complex concentrate was assessed. The mean dose of eptacog alfa was 30.95 mcg/kg b.w., and the total prothrombin complex factor concentrate dose was 14.17 mcg/kg b.w. After transfusion with red blood cell concentrate, fresh frozen plasma, and platelet concentrate, in the absence of improvement in the dynamics of postoperative drainage, it was decided to include recombinant human coagulation factor VIIa or a concentrate of all prothrombin complex factors in the treatment.
Results: After administration of recombinant human coagulation factor VIIa at a dose of 30.95 mcg/kg b.w., bleeding stopped in 12 patients, but the remaining 6 patients required reoperation due to persistently high drainage. The decision to perform a rethoracotomy was made by a team of cardiothoracic surgeons and anesthesiologists, taking into account the dynamics of drainage (bleeding) and the hemodynamic stability of the patient. After the administration of concentrate of all prothrombin complex factors at a dose of 14.17 U/kg b.w., bleeding stopped in 12 patients. Four patients required reoperation due to persistent bleeding.
Conclusions: Treatment with recombinant human coagulation factor VIIa and concentrate of all prothrombin complex factors is effective and safe for cardiac surgery patients.
Reference21 articles.
1. 1. Al Douri MA, Shafi T, Al Khdairi DA. Effect of the administration of recombinant activated factor VIIa in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis, 2000;11,(Suppl 1):121-127.
2. 2. Baral P, Cotter E, Gao G. Characteristics Associated with mortality in 372 patients receiving low-dose recombinant factor VIIa (rVIIa) for cardiac surgical bleeding. J Cardiothorac Vasc Anesth. 2019;33,(8):2133-2140.
3. 3. Korsak J. Ostra utrata krwi i jej leczenie. In: Łętowska M, Korsak J, eds. Transfuzjologia Kliniczna. Bielsko-Biała: Alfa-medica Press; 2009, p.71-81. (Polish)
4. 4. Szurlej D. Przetaczanie krwi i jej składników w kardiochirurgii. In: Łętowska M, Korsak J, eds. Transfuzjologia Kliniczna. Bielsko-Biała: Alfa-medica Press; 2009, p.151-154. (Polish)
5. 5. Kietaibl S, Ahmed A, Afshari A et al. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care. Second update 2022. Eur J Anaesthesiol. 2023;40:254-260.